- 积分
- 272
- 威望
- 272
- 包包
- 1059
|
Tissue Eng. 2006 Jul;12(7):2025-30.; F( \/ I) M7 h3 e/ s3 y& l! x
Antibiotics reduce the growth rate and differentiation of embryonic stem cell cultures. Z1 d1 }9 E5 n
Cohen S, Samadikuchaksaraei A, Polak JM, Bishop AE.
4 A3 ?9 _3 D- Y4 OSourceTissue Engineering and Regenerative Medicine Centre, Chelsea and Westminster Campus, Imperial College, London, UK.
$ _- A! h% h" {% f; X
4 |8 s: f( P/ |9 Q5 H1 NAbstract
- ~5 C8 K: F3 N$ M5 @$ dEmbryonic stem cells (ESCs) are being investigated increasingly for their potential as a cell source for tissue engineering. Antibiotics are regularly used in ESC culture media to control contamination, although they can be cytotoxic and interfere with protein synthesis. Our aim was to examine the effects of the frequently used antibiotics gentamicin and combined penicillin and streptomycin on ESC culture using differentiation of murine ESC into type II pneumocytes as a model. Antibiotics reduced the expression of the specific marker for type II pneumocytes, SPC mRNA, by up to 60%. We also identified an adverse effect on the growth rate of differentiating embryoid bodies, causing a significant ( p < 0.05) reduction of up to 40%, and an increase in population doubling time of up to 48%. No contamination was seen in any of the cultures. Our findings suggest that the routine use of antibiotics in ESC culture should be avoided as it may reduce the efficiency of the culture system.
: I8 q' x' |; w" g4 J4 x+ Q. S* N3 z& I4 Y; E
PMID: 16889530 [PubMed - indexed for MEDLINE]
; j! U* w4 V: }; f' \
! b8 t* s1 c8 j9 h# x5 @7 VClin Orthop Relat Res. 2006 Nov;452:242-9.6 ~: ?. q! L5 M% X
Toxic effects of gentamicin on marrow-derived human mesenchymal stem cells.
* `9 J9 e# P; `2 ~1 {: CChang Y, Goldberg VM, Caplan AI.
6 J, @- e1 V9 V5 dSourceSkeletal Research Center, Case Western Reserve University, Cleveland, OH 44106-7080, USA.
( a1 ^& a2 O) `; Z- K! M' a, F+ C2 B" T A% b2 c
Abstract# m5 n1 P' M7 @0 H% x
We hypothesized that the high concentrations of gentamicin achieved after local administration would have toxic effects on human mesenchymal stem cells. These cells were isolated from bone marrow from three healthy adult donors and cultured with different concentrations of gentamicin (0 microg/mL, 50 microg/mL, 100 microg/mL, and 200 microg/mL) for 7 days. After 7 days of gentamicin exposure, we examined cell viability, proliferation, and in vitro and in vivo osteochondrogenic capacity. Gentamicin did not have an adverse effect on the viability of human mesenchymal stem cells in all test groups, but did inhibit cell proliferation at concentrations of 100 microg/mL and 200 microg/mL. In in vitro osteogenesis, gentamicin decreased the DNA content and alkaline phosphatase activity of human mesenchymal stem cells at an early stage (Days 4 and 8) in a dose-dependent manner. For chondrogenesis, glycosaminoglycan content and Type II and Type X collagen deposition were lower in the pellets made with cells expanded in gentamicin at 100 or 200 microg/mL relative to cells expanded in medium without gentamicin. A comparable effect on osteochondrogenesis was observed in an in vivo model. At a high concentration, gentamicin inhibits proliferation and differentiation of human bone marrow mesenchymal stem cells and could compromise the bone-healing process.& t4 y/ N' v. S Y
. [4 `) A2 g: H) P% p
PMID: 16906089 [PubMed - indexed for MEDLINE] |
|